Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Oneview Healthcare is an Australian-based healthcare IT company specializing in cloud-based patient engagement and care experience platforms deployed primarily in acute care hospitals. The company operates in highly regulated healthcare markets including the US, Australia, UAE, and Ireland, selling software-as-a-service solutions that integrate with hospital EMR systems to deliver bedside patient engagement, digital wayfinding, and clinical workflow tools. With a $200M market cap, 20.6% revenue growth, but deeply negative margins (-92% operating, -105% net), this is a pre-profitability growth story burning cash to scale its installed base.
Oneview sells multi-year SaaS contracts to hospitals for patient engagement platforms that replace traditional nurse call systems and provide interactive bedside entertainment, education, and care coordination. Revenue model combines upfront implementation fees with recurring monthly per-bed licensing fees. Gross margins of 60% suggest software-centric economics, but the company is in land-and-expand mode, investing heavily in sales, R&D, and customer success to build market share before achieving operating leverage. Competitive advantage lies in deep EMR integrations (Epic, Cerner) and regulatory compliance in multiple jurisdictions, creating switching costs once deployed.
New hospital contract wins and total contracted bed count - each major health system win validates the platform and expands recurring revenue base
Annual recurring revenue (ARR) growth rate and net revenue retention metrics - indicates both new customer acquisition and expansion within existing accounts
Cash burn rate and runway to profitability - with negative FCF, quarterly cash consumption and balance sheet strength drive sentiment
Progress in key geographic markets, particularly US penetration where hospital IT budgets are largest and reimbursement models increasingly favor patient experience metrics
Intense competition from larger, well-capitalized healthcare IT vendors (Epic, Cerner/Oracle Health, GetWellNetwork) with broader product suites and existing hospital relationships - risk of being squeezed out or acquired at distressed valuation
Regulatory complexity across multiple jurisdictions (FDA software classification, HIPAA, GDPR, Australian privacy laws) creates compliance burden and slows international expansion
Technology disruption risk as AI-powered ambient listening and voice interfaces could bypass traditional bedside terminal hardware model
Large EMR vendors (Epic, Oracle) could bundle competing patient engagement modules into core offerings at marginal cost, leveraging installed base
Hospitals increasingly prefer integrated platforms over point solutions, favoring vendors with broader clinical workflow, analytics, and telehealth capabilities that Oneview may lack
Negative operating cash flow of approximately $8-10M annually (estimated from FCF data) with limited revenue base creates equity dilution risk if additional capital raises needed before profitability
Debt/Equity of 0.55 suggests some leverage, unusual for pre-profitable tech company - need to monitor covenant compliance and refinancing risk
Current ratio of 1.30 provides modest liquidity cushion but insufficient for extended cash burn without additional financing
moderate - Hospital capital expenditure budgets show some cyclical sensitivity, but healthcare IT spending has proven relatively resilient as digital transformation and patient experience scores (tied to Medicare reimbursement) are strategic priorities. Economic downturns may extend sales cycles and delay discretionary projects, but mission-critical infrastructure upgrades typically proceed. Government healthcare spending (Medicare/Medicaid in US, NHS-style systems elsewhere) provides countercyclical buffer.
High sensitivity through multiple channels: (1) Valuation multiple compression as rising rates reduce present value of distant cash flows for pre-profitable growth companies, (2) Hospital customers face higher financing costs for capital projects, potentially delaying IT infrastructure investments, (3) Company's own cost of capital increases if additional equity or debt financing needed to fund operations before profitability. Small-cap growth stocks with negative earnings typically see 20-30% valuation swings with 100bp rate moves.
Minimal direct credit exposure - SaaS model with monthly/quarterly billing reduces receivables risk. However, hospital financial health matters: stressed health systems may delay payments, renegotiate contracts, or defer expansion projects. Post-COVID, many hospitals face margin pressure from labor costs and lower patient volumes, which could impact IT budget flexibility.
growth - Pre-profitable, high-revenue-growth SaaS story attracts venture-style public market investors willing to accept near-term losses for potential market leadership. 20% revenue growth with negative margins and -20% one-year return suggests current holders are either long-term believers in the addressable market or underwater hoping for turnaround. Not suitable for value or income investors given negative earnings and no dividend. Requires high risk tolerance and 3-5 year horizon to potential profitability.
high - Micro-cap ($200M) pre-profitable growth stock with limited liquidity exhibits elevated volatility. Small absolute revenue base means individual contract wins/losses move the needle significantly. Highly sensitive to risk-on/risk-off sentiment, growth stock rotation, and healthcare IT sector momentum. Beta likely 1.5-2.0x market given size, profitability profile, and sector characteristics.